Neuroone Medical Technologies is trading 5.4% down at $1.92, after closing at $2.00 on August 26, 2026; no verified source identifies the cause of today’s decline.
- On August 27, the company announced successful robotic-assisted StereoCED drug-delivery procedures in large animals, without linking the release to share-price activity.
- Recent earnings commentary highlighted manufacturing constraints, wider losses, and reduced fiscal 2026 revenue guidance.